Inspired by the Pandemic, Emergency Physicians and Florida Firm ROBRADY design, Launch the World’s 1st Ultraportable, Ultra-quiet Negative Pressure ULPA Filtration System

Emergency physicians teamed with ROBRADY, a world-class product development firm, to create a portable negative pressure ULPA (Ultra Low Particulate Air) filtration system used by healthcare providers in any healthcare setting while administering patient care, lifesaving respiratory treatments and procedures or during patient transport.

This innovative system utilizes an ultra-quiet negative pressure generator weighing less than 7 pounds with a family of attachments turning any emergency or non-emergency healthcare setting into a negative pressure isolation environment. The system adds an additional layer of protection for the healthcare provider against airborne contaminants produced during common treatments and life-saving aerosol-generating procedures, such as nebulizers, continuous positive airway ventilation (CPAP), intubation, and more.

Rick Blubaugh, DO., a board-certified emergency physician and inventor says, “Many common life-saving procedures that have been done for decades in medical care have been severely restricted during the pandemic due to the danger of contaminating the healthcare providers who are performing these treatments. We could not stand by and watch without doing something that changed the situation for our patients and colleagues. This allows us to get back to safely delivering that care when it is needed most.” While the system from SafER Medical Products, LLC is COVID-inspired, it can and should be used to help mitigate exposure from any airborne pathogens that healthcare personnel are routinely exposed to.

The system is FDA listed and in use by several hospitals and EMS agencies. Research paths are underway with physicians and scientists from Oklahoma State University, University of Missouri, Massachusetts College of Pharmacy and Health Sciences, and the National Physical Laboratory in the UK. Dr. Blubaugh sees the SafER system becoming the new standard of care for aerosol-generating procedures and “the Latex glove of the 21st century”. The SafER and ROBRADY team work around the clock to produce and deliver the system across the country and soon to distribute this life-saving protection globally.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”